# Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

> **NCT06283550** · PHASE2 · COMPLETED · sponsor: **Innovaderm Research Inc.** · enrollment: 82 (actual)

## Conditions studied

- Chronic Hand Eczema

## Interventions

- **DRUG:** Abrocitinib 200 mg
- **DRUG:** Abrocitinib 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06283550
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-31
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-11-03
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06283550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06283550, "Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06283550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*